Latest Industry Insights

Whilst scientists work tirelessly to develop an effective COVID-19 vaccine as a long-term preventive strategy, in parallel, researchers are also exploring the therapeutic potential of existing drugs as an efficient immediate approach. We recently had the pleasure of speaking with Alan Fletcher, VP/GM, Life Sciences at PerkinElmer, Inc. to learn about the benefits and challenges of repurposing a drug in this context.

The COVID-19 outbreak has accelerated the digitization of healthcare. “Digital pharmacy” Genius Rx says it will trial same-day couriered delivery of scripts to patients’ doors from this summer. We spoke to Randy about the process of getting medication online and how analytics technology could save patients money.

Technology Networks spoke with David Dodd, President and CEO of GeoVax, to learn more about the vaccine candidates against COVID-19, what progress has been made in clinical testing and how the company is working to accelerate vaccine development timeframes.

Technology Networks spoke to Trey Martin, President, IDT, to find out exactly how primers and probes work, and learn about the important role they can play in COVID-19 testing.

Lab efficiency is critical to speeding up development processes, yet many researchers find they spend more time managing consumables data than working at the bench. Lab informatics is one solution to this problem.

Technology Networks spoke with Amelie Boulais, Vaccine Marketing Manager, Sartorius, to find out more about how Sartorius is supporting vaccine development at this critical time and the power of collaboration.

Technology Networks recently had the pleasure of speaking with Novavax to discuss their current progress in COVID-19 vaccine development.

The Feinstein Institutes is collaborating with Gilead Sciences and Regeneron Pharmaceuticals in an effort to identify effective therapeutic treatments against COVID-19. Technology Networks recently had the pleasure of speaking with Kevin Tracey, CEO and President of the Feinstein Institutes for Medical Research to find out more.

Technology Networks spoke with Yossi Pollak, CEO, Sight Diagnostics, to learn more about OLO and how it is being used to minimize the challenges of handling and analyzing blood samples from COVID-19 infected patients.

Early stage biotech company Aqualung Therapeutics is currently developing a therapeutic monoclonal antibody – ALT-100 – for the treatment of unchecked inflammation. COVID-19 can cause severe pneumonia and respiratory failure. There is therefore a potential option to treat patients diagnosed with COVID-19 with ALT-100. Technology Networks recently spoke with Joe Garcia, MD, Founder and Chief Executive Officer of Aqualung Therapeutics to learn more.